Professional Documents
Culture Documents
This is a list of infectious diseases arranged by name, along with the infectious agents that cause them, the vaccines that can prevent or cure them when they exist
and their current status.
List
Infectious agent Common name Signs and symptoms Diagnosis Treatment Current status Vaccin
Actinomyces israelii,
Actinomyces
Penicillin, doxycycline, and
gerencseriae and Actinomycosis Painful abscesses Histologic findings No
sulfonamides
Propionibacterium
propionicus
Fexinidazole by mouth or
Hemolymphatic phase: pentamidine by injection for T. Undergoing
Fever, b. gambiense. worldwide
Identification of elimination as a
African sleeping lymphadenopathy trypanosomes in a sample Und
Trypanosoma brucei sickness (African Suramin by injection is public health
Neurological phase: by microscopic resear
trypanosomiasis) problem and
Sleep disorders, examination used for T. b. regional
neurological symptoms, rhodesiense
psychiatric symptoms control[2]
Ascaris lumbricoides Ascariasis Migrating larvae, intestinal Fecal smear Albendazole, mebendazole, No
blockage, and bowel levamisole and pyrantel
obstruction pamoate
Increased vaginal
List of bacterial
Bacterial vaginosis discharge that usually Gram stain and whiff test Metronidazole or clindamycin No
vaginosis microbiota
smells like fish
Bacteroides species Bacteroides infection No
Intermittent diarrhea,
constipation, vomiting,
microscopic examination of
abdominal pain, anorexia, Tetracycline, metronidazole or
Balantidium coli Balantidiasis stools, or colonoscopy or No
weight loss, headache, iodoquinol
sigmoidoscopy
colitis, and marked fluid
loss
usually asymptomatic;
BK virus BK virus infection No
fever, difficulty urinating
Aminoglycosides such as
streptomycin and gentamicin, Und
Chills, malaise, high fever,
Yersinia pestis Bubonic plague Culture tetracyclines (especially
muscle cramps, seizures resear
doxycycline), and the
fluoroquinolone ciprofloxacin
Intestinal disease by
Capillaria philippinensis,
hepatic disease by
Capillariasis No
Capillaria hepatica and
pulmonary disease by
Capillaria aerophila
Fluoroquinolones (such as
Peripheral blood smear with ciprofloxacin) or
Fever, pale appearance,
Giemsa stain, Columbia chloramphenicol in adults and
malaise, painless liver
blood agar cultures, chloramphenicol plus beta-
Bartonella bacilliformis Carrion's disease enlargement, jaundice, No
immunoblot, indirect lactams in children are the
enlarged lymph nodes, and
immunofluorescence, and antibiotic regimens of choice
enlarged spleen
PCR during the acute phase of
Carrion's disease.
Malaise, decreased
Bartonella henselae Cat-scratch disease Polymerase chain reaction Azithromycin No
appetite, and aches
usually Group A Penicillinase-resistant
An area that is red, hot, By history and physical
Streptococcus and Cellulitis semisynthetic penicillin or a No
and painful examination
Staphylococcus first-generation cephalosporin
Microscopic examination of
fresh anticoagulated blood, Undergoing
Fever, malaise, headache, or its buffy coat, for motile Benznidazole and nifurtimox elimination of
Chagas disease
and enlargement of the parasites; or by preparation (though benznidazole is the human Und
Trypanosoma cruzi (American
liver, spleen, and lymph of thin and thick blood only drug available in most of transmissions researc
trypanosomiasis)
nodes smears stained with Latin America) and regional
Giemsa, for direct control[9]
visualization of parasites
Chlamydia trachomatis Chlamydia In women, those who have Nucleic acid amplification azithromycin, doxycycline, No
an asymptomatic infection tests (NAAT), such as erythromycin, levofloxacin or
that is not detected by their polymerase chain reaction ofloxacin
doctor, approximately half (PCR), transcription
will develop pelvic mediated amplification
inflammatory disease (TMA), and the DNA strand
(PID), displacement amplification
(SDA)
In men, painful or
burning sensation
when urinating
Chlamydophila
pneumoniae infection
Chlamydophila
(Taiwan acute No
pneumoniae
respiratory agent or
TWAR)
Crimean-Congo
Crimean-Congo
hemorrhagic fever No
hemorrhagic fever virus
(CCHF)
usually Ancylostoma
Cutaneous larva
braziliense; multiple No
migrans (CLM)
other parasites
Cyclospora
Cyclosporiasis No
cayetanensis
Taenia solium Cysticercosis No
Corynebacterium Diphtheria fever of 38 °C (100.4 °F) or Laboratory criteria Metronidazole, Erythromycin, Yes
diphtheriae above; chills; fatigue; Procaine penicillin G
bluish skin coloration Isolation of C.
(cyanosis); sore throat; diphtheriae culture
hoarseness; cough; Histopathologic
headache; difficulty diagnosis
swallowing; painful
swallowing; difficulty
breathing; rapid breathing;
Toxin demonstration
foul-smelling and
bloodstained nasal In vivo tests (guinea
pig inoculation)
discharge; and In vitro test: Elek's gel
lymphadenopathy precipitation test, PCR,
ELISA, ICA
Clinical criteria
Diphyllobothrium Diphyllobothriasis No
Undergoing
Burning pain, blister from
Dracunculus medinensis Dracunculiasis worldwide No
which worm emerges
eradication
High fever, muscle pain,
Corticosteroids,
altered mental status, Und
Eastern equine Eastern equine anticonvulsants, and
headache, meningeal Blood tests
encephalitis virus encephalitis (EEE) supportive measures (treating researc
irritation, photophobia, and
symptoms)
seizures
Und
Ehrlichia species Ehrlichiosis
researc
Anal itching that gets
Enterobiasis (Pinworm
Enterobius vermicularis worse at night, disturbed No
infection)
sleep
Erythema infectiosum
Parvovirus B19 No
(Fifth disease)
Human herpesvirus 6
Exanthem subitum
(HHV-6) and human No
(Sixth disease)
herpesvirus 7 (HHV-7)
Fasciola hepatica and
Fasciolasis No
Fasciola gigantica
Gerstmann-Sträussler-
PRNP Scheinker syndrome No
(GSS)
Gnathostoma spinigerum
and Gnathostoma Gnathostomiasis No
hispidum
Hantavirus Pulmonary
Sin Nombre virus No
Syndrome (HPS)
Heartland virus Heartland virus disease No
Helicobacter pylori
Helicobacter pylori Stomach ulcers No
infection
thrombocytopenia and
microangiopathic
hemolysis, plus one or
more of the following:
neurological symptoms
(e.g., confusion, cerebral First diagnosis of aHUS is
convulsions, seizures); often made in the context
renal impairment (e.g., of an initial, complement- Treatment involves supportive
Escherichia coli
Hemolytic-uremic elevated creatinine, triggering infection, and care and may include dialysis,
O157:H7, O111 and No
syndrome (HUS) decreased estimated Shiga-toxin has also been steroids, blood transfusions,
O104:H4
glomerular filtration rate implicated as a trigger that and plasmapheresis.
[eGFR], abnormal identifies patients with
urinalysis); and aHUS.
gastrointestinal (GI)
symptoms (e.g., diarrhea,
nausea/vomiting,
abdominal pain,
gastroenteritis).
Redness of cheeks and
HFRS is difficult to
nose, fever, chills, sweaty There is no cure for HFRS.
diagnose on clinical
Hemorrhagic fever with palms, diarrhea, malaise, Treatment involves supportive
Bunyaviridae species grounds alone and No
renal syndrome (HFRS) headaches, nausea, therapy including renal
serological evidence is
abdominal and back pain, dialysis.
often needed.
respiratory problems
Hepatitis E virus Hepatitis E Nausea, jaundice Hepatitis E virus (HEV) Rest, ribavirin (if chronic) Yes
fever
severe headache
muscle aches (myalgia)
chills and shaking,
similar to the
symptoms of influenza
Anaplasma Human granulocytic
nausea PCR Doxycycline No
phagocytophilum anaplasmosis (HGA)
vomiting
loss of appetite
unintentional weight
loss
abdominal pain
cough
Human Human
metapneumovirus metapneumovirus No
(hMPV) infection
Epstein–Barr virus Epstein–Barr virus Diagnostic modalities for Infectious mononucleosis is Und
(EBV) infectious Fever – usually lasting infectious mononucleosis generally self-limiting, so only researc
mononucleosis (Mono) 14 days; often mild include: symptomatic or supportive
Sore throat – usually treatments are used.
severe for 3–5 days, Person's age, with
before resolving in the highest risk at 10 to 30
next 7–10 days. years.
Swollen glands – Medical history, such
mobile; usually located as close contact with
around the back of the other people with
neck (posterior cervical infectious
lymph nodes) and mononucleosis, and the
sometimes throughout presence and time of
the body. onset of
"mononucleosis-like
symptoms" such as
fever and sore throat.
Physical examination,
including palpation of
any enlarged lymph
nodes in the neck, or
enlarged spleen.
The heterophile
antibody test is a
screening test that
gives results within a
day, but has
significantly less than
full sensitivity (70–
92%) in the first two
weeks after clinical
symptoms begin.
Serological tests take
longer time than the
heterophile antibody
test, but are more
accurate.
Neisseria meningitidis Meningococcal disease Flu-like symptoms, stiff Treatment in primary care Yes
neck, altered mental usually involves prompt
status, seizures, purpura intramuscular administration of
benzylpenicillin, and then an
urgent transfer to hospital
(hopefully, an academic level I
medical center, or at least a
hospital with round the clock
neurological care, ideally with
neurological intensive and
critical care units) for further
care. Once in the hospital, the
antibiotics of choice are
usually IV broad spectrum 3rd
generation cephalosporins,
e.g., cefotaxime or
ceftriaxone. Benzylpenicillin
and chloramphenicol are also
effective.
Metagonimiasis is
usually Metagonimus Diarrhea and colicky
Metagonimiasis diagnosed by eggs seen in Praziquantel No
yokagawai abdominal pain
feces.
Fumagillin has been used in
Microsporidia phylum Microsporidiosis PCR the treatment. Another agent No
used is albendazole.
Headache, fever, muscle Early diagnosis continued The most effective antibiotics
Murine typhus (Endemic
Rickettsia typhi pain, joint pain, nausea and to be based on clinical include tetracycline and No
typhus)
vomiting suspicion. chloramphenicol.
numerous species of
Triad: painless firm skin
bacteria Ultrasound, fine needle Antibiotics or antifungal
Mycetoma lump, multiple weeping No
(Actinomycetoma) and aspiration medication
sinuses, grainy discharge
fungi (Eumycetoma)
parasitic dipterous fly Examination and serologic Petroleum jelly over the
Myiasis Boil with larva inside No
larvae testing central punctum
most commonly
Neonatal conjunctivitis Antibiotic ointment
Chlamydia trachomatis
(Ophthalmia (erythromycin, tetracycline, or No
and Neisseria
neonatorum) rarely silver nitrate or Argyrol)
gonorrhoeae
Und
Nipah virus Nipah virus infection
researc
usually Nocardia Nocardiosis Pulmonary infection chest x-ray to analyze the trimethoprim/sulfamethoxazole No
asteroides and other lungs, a bronchoscopy, a or high doses of sulfonamides
Nocardia species Night sweats, fever, brain/lung/skin biopsy, or a
cough, chest pain sputum culture.
Neurological
infection
Headache, lethargy,
confusion, seizures,
sudden onset of
neurological deficit
Cardiac conditions
In recorded cases, it
has caused damage to
heart valves whether
natural or prosthetic
Lymphocutaneous
disease
Nocardial cellulitis is
akin to erysipelas but is
less acute
Ocular disease
Disseminated
nocardiosis
Fever, moderate or very
high can be seen
Undergoing
elimination in
Onchocerciasis (River the WHO Und
Onchocerca volvulus
blindness) regions of the researc
Americas and
Africa[37]
Opisthorchis viverrini
and Opisthorchis Opisthorchiasis No
felineus
Paracoccidioidomycosis
Paracoccidioides
(South American No
brasiliensis
blastomycosis)
usually Paragonimus
westermani and other Paragonimiasis No
Paragonimus species
Miltefosine, fluconazole,
Primary amoebic Fever, vomiting, stiff neck, amphotericin B,
usually Naegleria fowleri meningoencephalitis seizures, poor coordination, flagellation test posaconazole, voriconazole, No
(PAM) confusion, death targeted temperature
management
clumsiness, progressive
Progressive multifocal weakness, and visual, finding JC virus DNA in
JC virus No
leukoencephalopathy speech, and sometimes spinal fluid, brain CT
personality changes
tetracyclines and
Chlamydophila psittaci Psittacosis severe pneumonia Culture No
chloramphenicol
Undergoing
Rubella virus Rubella regional Yes
elimination[41]
Salmonella species Salmonellosis No
Group A Streptococcus
Scarlet fever No
species
Undergoing
regional
elimination and
Und
Schistosoma species Schistosomiasis being
eliminated as a researc
public health
problem[43]
multiple Sepsis No
Shigellosis (bacillary
Shigella species No
dysentery)
Varicella zoster virus Shingles (Herpes
(VZV) zoster) Yes[
Staphylococcal
Staphylococcus species No
infection
Strongyloides stercoralis Strongyloidiasis No
Subacute sclerosing
Measles virus Yes
panencephalitis
Yaws is
Bejel, Syphilis, and undergoing Und
Treponema pallidum worldwide
Yaws researc
eradication[46]
Taenia species Taeniasis No
usually Epidermophyton
floccosum, Trichophyton
rubrum, and Tinea cruris (Jock itch) No
Trichophyton
mentagrophytes
Tinea manum (ringworm
Trichophyton rubrum No
of the hand)
usually Hortaea
Tinea nigra No
werneckii
Undergoing
regional
elimination and
Chlamydia trachomatis Trachoma worldwide No
elimination as a
public health
problem[50]
Trichinella spiralis Trichinosis No
Undergoing
worldwide
usually Mycobacterium
Tuberculosis elimination as a Yes
tuberculosis
public health
problem
Und
Francisella tularensis Tularemia
researc
Salmonella enterica
subsp. enterica, serovar Typhoid fever Yes
typhi
Rickettsia Typhus fever No
Ureaplasma urealyticum
Ureaplasma urealyticum No
infection
Coccidioides immitis or
Coccidioides Valley fever No
posadasii.[52]
Vibrio vulnificus
Vibrio vulnificus No
infection
Vibrio parahaemolyticus
Vibrio parahaemolyticus No
enteritis
multiple viruses Viral pneumonia No
Und
West Nile virus West Nile fever
researc
Yersinia
Yersinia
pseudotuberculosis No
pseudotuberculosis
infection
Yersinia enterocolitica Yersiniosis No
See also
Infections associated with diseases
List of oncogenic bacteria
List of causes of death by rate − including specific infectious diseases and classes thereof
List of human disease case fatality rates
List of vaccine topics
References
1. Kuschner, R. A.; Russell, K. L.; Abuja, M.; Bauer, K. M.; Faix, D. J.; 12. Kim, D. S.; Nam, J. H. (2010). "Characterization of attenuated
Hait, H.; Henrick, J.; Jacobs, M.; Liss, A.; Lynch, J. A.; Liu, Q.; Lyons, coxsackievirus B3 strains and prospects of their application as live-
A. G.; Malik, M.; Moon, J. E.; Stubbs, J.; Sun, W.; Tang, D.; Towle, A. attenuated vaccines". Expert Opinion on Biological Therapy. 10 (2):
C.; Walsh, D. S.; Wilkerson, D.; Adenovirus Vaccine Efficacy Trial 179–190. doi:10.1517/14712590903379502 (https://doi.org/10.151
Consortium (2013). "A phase 3, randomized, double-blind, placebo- 7%2F14712590903379502). PMID 20088713 (https://pubmed.ncbi.
controlled study of the safety and efficacy of the live, oral nlm.nih.gov/20088713). S2CID 2700243 (https://api.semanticschola
adenovirus type 4 and type 7 vaccine, in U.S. Military recruits". r.org/CorpusID:2700243).
Vaccine. 31 (28): 2963–2971. doi:10.1016/j.vaccine.2013.04.035 (ht 13. Schleiss, M. R. (2008). "Cytomegalovirus vaccine development".
tps://doi.org/10.1016%2Fj.vaccine.2013.04.035). PMID 23623865 Human Cytomegalovirus. Current Topics in Microbiology and
(https://pubmed.ncbi.nlm.nih.gov/23623865). Immunology. Vol. 325. pp. 361–382. doi:10.1007/978-3-540-77349-
2. "Trypanosomiasis, human African (sleeping sickness)" (https://www. 8_20 (https://doi.org/10.1007%2F978-3-540-77349-8_20).
who.int/news-room/fact-sheets/detail/trypanosomiasis-human-africa ISBN 978-3-540-77348-1. PMC 2831992 (https://www.ncbi.nlm.nih.
n-(sleeping-sickness)). www.who.int. Retrieved 2023-06-16. gov/pmc/articles/PMC2831992). PMID 18637516 (https://pubmed.n
3. La Greca, F.; Magez, S. (2011). "Vaccination against cbi.nlm.nih.gov/18637516).
trypanosomiasis: Can it be done or is the trypanosome truly the 14. Pandya, J.; Gorchakov, R.; Wang, E.; Leal, G.; Weaver, S. C. (2012).
ultimate immune destroyer and escape artist?" (https://www.ncbi.nl "A vaccine candidate for eastern equine encephalitis virus based
m.nih.gov/pmc/articles/PMC3323498). Human Vaccines. 7 (11): on IRES-mediated attenuation" (https://www.ncbi.nlm.nih.gov/pmc/a
1225–1233. doi:10.4161/hv.7.11.18203 (https://doi.org/10.4161%2F rticles/PMC3283035). Vaccine. 30 (7): 1276–1282.
hv.7.11.18203). PMC 3323498 (https://www.ncbi.nlm.nih.gov/pmc/ar doi:10.1016/j.vaccine.2011.12.121 (https://doi.org/10.1016%2Fj.vac
ticles/PMC3323498). PMID 22205439 (https://pubmed.ncbi.nlm.nih. cine.2011.12.121). PMC 3283035 (https://www.ncbi.nlm.nih.gov/pm
gov/22205439). c/articles/PMC3283035). PMID 22222869 (https://pubmed.ncbi.nlm.
4. "Researchers a step closer to making HIV vaccine" (http://www.med nih.gov/22222869).
icalnewstoday.com/articles/258647.php). Medical News Today. 15. Rudoler, N.; Baneth, G.; Eyal, O.; Van Straten, M.; Harrus, S. (2012).
April 5, 2013. Retrieved April 24, 2013. "Evaluation of an attenuated strain of Ehrlichia canis as a vaccine
5. Enria, Delia A.; Ambrosio, Ana M.; Briggiler, Ana M.; Feuillade, for canine monocytic ehrlichiosis". Vaccine. 31 (1): 226–233.
María R.; Crivelli, Eleonora; Grupo de Estudio de la Vacuna contra doi:10.1016/j.vaccine.2012.10.003 (https://doi.org/10.1016%2Fj.vac
la Fiebre Hemorrágica Argentina (2010). "Vacuna contra la Fiebre cine.2012.10.003). PMID 23072894 (https://pubmed.ncbi.nlm.nih.go
Hemorragica Argentina Candid#1 producida en la Argentina. v/23072894).
Inmunogenicidad y seguridad" (https://www.medicinabuenosaires.c 16. "Collaboration to develop the world's first prophylactic gonorrhoea
om/demo/revistas/vol70-10/3/v70_n3_p215_222.pdf) [Candid#1 vaccine" (https://web.archive.org/web/20200902235718/https://ww
vaccine against Argentine hemorrhagic fever produced in w.europeanpharmaceuticalreview.com/news/126412/collaboration-t
Argentina. Immunogenicity and safety] (PDF). Medicina (in o-develop-the-worlds-first-prophylactic-gonorrhoea-vaccine/).
Spanish). 70 (3): 215–22. PMID 20529769 (https://pubmed.ncbi.nl Archived from the original (https://www.europeanpharmaceuticalrevi
m.nih.gov/20529769). ew.com/news/126412/collaboration-to-develop-the-worlds-first-prop
6. Negrón, María E.; Kharod, Grishma A.; Bower, William A.; Walke, hylactic-gonorrhoea-vaccine/) on 2020-09-02.
Henry (22 February 2019). "Notes from the Field: Human Brucella 17. Zhu, F. C.; Liang, Z. L.; Li, X. L.; Ge, H. M.; Meng, F. Y.; Mao, Q. Y.;
abortus RB51 Infections Caused by Consumption of Unpasteurized Zhang, Y. T.; Hu, Y. M.; Zhang, Z. Y.; Li, J. X.; Gao, F.; Chen, Q. H.;
Domestic Dairy Products — United States, 2017–2019" (https://ww Zhu, Q. Y.; Chu, K.; Wu, X.; Yao, X.; Guo, H. J.; Chen, X. Q.; Liu, P.;
w.ncbi.nlm.nih.gov/pmc/articles/PMC6385706). Morbidity and Dong, Y. Y.; Li, F. X.; Shen, X. L.; Wang, J. Z. (2013).
Mortality Weekly Report. 68 (7): 185. "Immunogenicity and safety of an enterovirus 71 vaccine in healthy
doi:10.15585/mmwr.mm6807a6 (https://doi.org/10.15585%2Fmmwr. Chinese children and infants: A randomised, double-blind, placebo-
mm6807a6). PMC 6385706 (https://www.ncbi.nlm.nih.gov/pmc/articl controlled phase 2 clinical trial". The Lancet. 381 (9871): 1037–45.
es/PMC6385706). PMID 30789879 (https://pubmed.ncbi.nlm.nih.go doi:10.1016/S0140-6736(12)61764-4 (https://doi.org/10.1016%2FS
v/30789879). 0140-6736%2812%2961764-4). PMID 23352749 (https://pubmed.n
7. Titball, R. W.; Williamson, E. D. (2004). "Yersinia pestis (plague) cbi.nlm.nih.gov/23352749). S2CID 27961719 (https://api.semantics
vaccines". Expert Opinion on Biological Therapy. 4 (6): 965–973. cholar.org/CorpusID:27961719).
doi:10.1517/14712598.4.6.965 (https://doi.org/10.1517%2F147125 18. Kim, D. S.; Nam, J. H. (2010). "Characterization of attenuated
98.4.6.965). PMID 15174978 (https://pubmed.ncbi.nlm.nih.gov/1517 coxsackievirus B3 strains and prospects of their application as live-
4978). S2CID 43565534 (https://api.semanticscholar.org/CorpusID: attenuated vaccines". Expert Opinion on Biological Therapy. 10 (2):
43565534). 179–190. doi:10.1517/14712590903379502 (https://doi.org/10.151
8. Shivakumar, K. M.; Vidya, S. K.; Chandu, G. N. (2009). "Dental 7%2F14712590903379502). PMID 20088713 (https://pubmed.ncbi.
caries vaccine" (https://doi.org/10.4103%2F0970-9290.49066). nlm.nih.gov/20088713). S2CID 2700243 (https://api.semanticschola
Indian Journal of Dental Research. 20 (1): 99–106. r.org/CorpusID:2700243).
doi:10.4103/0970-9290.49066 (https://doi.org/10.4103%2F0970-92 19. "Hepatitis C vaccine by Inovio could be tested in humans by end of
90.49066). PMID 19336869 (https://pubmed.ncbi.nlm.nih.gov/19336 year" (http://www.bizjournals.com/philadelphia/news/2013/01/09/he
869). patitis-c-vaccine-by-inovio-could-be.html). Philadelphia Business
9. https://www.who.int/news-room/fact-sheets/detail/chagas-disease- Journal. January 9, 2013. Retrieved April 24, 2013.
(american-trypanosomiasis) (https://www.who.int/news-room/fact-sh 20. "Human hookworm vaccine trial" (http://www.medicalnewstoday.co
eets/detail/chagas-disease-(american-trypanosomiasis)). {{cite m/articles/240586.php). Medical News Today. January 20, 2012.
web}}: Missing or empty |title= (help) Retrieved April 24, 2013.
10. "Potential Chagas Vaccine Candidate Shows Unprecedented 21. Hanabuchi, S.; Ohashi, T.; Koya, Y.; Kato, H.; Hasegawa, A.;
Efficacy" (https://www.sciencedaily.com/releases/2013/03/1303261 Takemura, F.; Masuda, T.; Kannagi, M. (5 December 2001).
94104.htm). Science Daily. 26 March 2013. Retrieved "Regression of Human T-cell Leukemia Virus Type I (HTLV-I)-
14 September 2013. Associated Lymphomas in a Rat Model: Peptide-Induced T-Cell
11. Docksai, Rick (31 May 2017). "DoD Vaccine Research Saves Immunity" (https://doi.org/10.1093%2Fjnci%2F93.23.1775). Journal
Military, Civilian Lives" (https://www.defense.gov/News/Article/Articl of the National Cancer Institute. 93 (23): 1775–1783.
e/1198160/dod-vaccine-research-saves-military-civilian-lives/). US doi:10.1093/jnci/93.23.1775 (https://doi.org/10.1093%2Fjnci%2F93.
Department of Defense. Retrieved 7 July 2018. 23.1775). PMID 11734593 (https://pubmed.ncbi.nlm.nih.gov/117345
93).
22. De Thé, G.; Bomford, R.; Kazanji, M.; Ibrahim, F. (2007). "Human T 40. Lindell, D. M.; Morris, S. B.; White, M. P.; Kallal, L. E.; Lundy, P. K.;
Cell Lymphotropic Virus: Necessity for and Feasibility of a Vaccine". Hamouda, T.; Baker, J. R.; Lukacs, N. W. (2011). Semple, Malcolm
Ciba Foundation Symposium 187 - Vaccines Against Virally Gracie (ed.). "A Novel Inactivated Intranasal Respiratory Syncytial
Induced Cancers. Novartis Foundation Symposia. Vol. 187. pp. 47– Virus Vaccine Promotes Viral Clearance without Th2 Associated
60. doi:10.1002/9780470514672.ch4 (https://doi.org/10.1002%2F97 Vaccine-Enhanced Disease" (https://www.ncbi.nlm.nih.gov/pmc/arti
80470514672.ch4). ISBN 978-0-470-51467-2. PMID 7796676 (http cles/PMC3137595). PLOS ONE. 6 (7): e21823.
s://pubmed.ncbi.nlm.nih.gov/7796676). Bibcode:2011PLoSO...621823L (https://ui.adsabs.harvard.edu/abs/
23. Hanabuchi, S.; Ohashi, T.; Koya, Y.; Kato, H.; Hasegawa, A.; 2011PLoSO...621823L). doi:10.1371/journal.pone.0021823 (https://
Takemura, F.; Masuda, T.; Kannagi, M. (2001). "Regression of doi.org/10.1371%2Fjournal.pone.0021823). PMC 3137595 (https://
human T-cell leukemia virus type I (HTLV-I)-associated lymphomas www.ncbi.nlm.nih.gov/pmc/articles/PMC3137595). PMID 21789184
in a rat model: Peptide-induced T-cell immunity" (https://doi.org/10.1 (https://pubmed.ncbi.nlm.nih.gov/21789184).
093%2Fjnci%2F93.23.1775). Journal of the National Cancer 41. "Rubella" (https://www.who.int/news-room/fact-sheets/detail/rubell
Institute. 93 (23): 1775–1783. doi:10.1093/jnci/93.23.1775 (https://d a). www.who.int. Retrieved 2023-06-16.
oi.org/10.1093%2Fjnci%2F93.23.1775). PMID 11734593 (https://pu 42. Jiang, S.; Lu, L.; Du, L. (2013). "Development of SARS vaccines
bmed.ncbi.nlm.nih.gov/11734593). and therapeutics is still needed" (https://www.ncbi.nlm.nih.gov/pmc/
24. De Thé, G.; Bomford, R.; Kazanji, M.; Ibrahim, F. (1994). "Human T articles/PMC7079997). Future Virology. 8 (1): 1–2.
cell lymphotropic virus: Necessity for and feasibility of a vaccine". doi:10.2217/fvl.12.126 (https://doi.org/10.2217%2Ffvl.12.126).
Ciba Foundation Symposium. Novartis Foundation Symposia. 187: PMC 7079997 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079
47–55, discussion 55–60. doi:10.1002/9780470514672.ch4 (https:// 997). PMID 32201503 (https://pubmed.ncbi.nlm.nih.gov/32201503).
doi.org/10.1002%2F9780470514672.ch4). ISBN 9780470514672. 43. "Schistosomiasis" (https://www.who.int/news-room/fact-sheets/detai
PMID 7796676 (https://pubmed.ncbi.nlm.nih.gov/7796676). l/schistosomiasis). www.who.int. Retrieved 2023-06-16.
25. Pullen, L.C. (November 7, 2011). "Epstein-Barr Virus Vaccine May 44. Siddiqui, A. A.; Siddiqui, B. A.; Ganley-Leal, L. (2011).
Soon Enter Phase 3 Trial" (http://www.medscape.com/viewarticle/7 "Schistosomiasis vaccines" (https://www.ncbi.nlm.nih.gov/pmc/articl
53031). Medscape Today. Retrieved April 24, 2013. es/PMC3323497). Human Vaccines. 7 (11): 1192–1197.
26. "H5N1 Influenza Virus Vaccine, manufactured by Sanofi Pasteur, doi:10.4161/hv.7.11.17017 (https://doi.org/10.4161%2Fhv.7.11.1701
Inc. Questions and Answers" (https://www.fda.gov/vaccines-blood-b 7). PMC 3323497 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3
iologics/vaccines/h5n1-influenza-virus-vaccine-manufactured-sanof 323497). PMID 22048120 (https://pubmed.ncbi.nlm.nih.gov/220481
i-pasteur-inc-questions-and-answers#:~:text=On%20April%2017%2 20).
C%202007%2C%20FDA,to%20the%20H5N1%20influenza%20vir 45. This article incorporates text from this source, which is in the
us). FDA. 12 April 2019. public domain: Lopez A, Harrington T, Marin M (2015). "Chapter 22:
27. Nakkazi, E. (March 12, 2012). "New vaccine trials to prevent Varicella" (https://www.cdc.gov/vaccines/pubs/pinkbook/varicella.ht
visceral leishmaniasis" (http://newsciencejournalism.com/03/2012/v ml). In Hamborsky J, Kroger A, Wolfe S (eds.). Epidemiology and
accine-trials-to-prevent-visceral-leishmaniasis-starts/). New Prevention of Vaccine-Preventable Diseases (https://www.cdc.gov/v
Science Journalism. Retrieved June 16, 2013. accines/pubs/pinkbook/index.html) (13th ed.). Washington D.C.:
28. "Leprosy" (https://www.who.int/news-room/fact-sheets/detail/lepros U.S. Centers for Disease Control and Prevention (CDC). ISBN 978-
y). www.who.int. Retrieved 2023-06-16. 0990449119.
29. McGuinness, R. (November 20, 2012). "Search for leprosy vaccine 46. "Yaws" (https://www.who.int/news-room/fact-sheets/detail/yaws).
continues as disease still affects thousands" (http://metro.co.uk/201 www.who.int. Retrieved 2023-06-16.
2/11/20/search-for-leprosy-vaccine-continues-as-disease-still-affect 47. Cullen, P. A.; Cameron, C. E. (2006). "Progress towards an effective
s-thousands-620746/). Metro News. Retrieved May 29, 2013. syphilis vaccine: The past, present and future". Expert Review of
30. "Lyme Disease Vaccine" (http://www.lymeinfo.net/vaccine.html). Vaccines. 5 (1): 67–80. doi:10.1586/14760584.5.1.67 (https://doi.or
Lyme Info. Retrieved April 24, 2013. g/10.1586%2F14760584.5.1.67). PMID 16451109 (https://pubmed.
31. "Lymphatic filariasis" (https://www.who.int/news-room/fact-sheets/de ncbi.nlm.nih.gov/16451109). S2CID 31534855 (https://api.semantic
tail/lymphatic-filariasis). www.who.int. Retrieved 2023-06-16. scholar.org/CorpusID:31534855).
32. Hampton, T. (2006). "Marburg Vaccine Shows Promise: Offers 48. Guilherme, L.; Ferreira, F. M.; Köhler, K. F.; Postol, E.; Kalil, J.
Postexposure Protection in Monkeys". JAMA. 295 (20): 2346. (2013). "A Vaccine against Streptococcus pyogenes" (https://doi.or
doi:10.1001/jama.295.20.2346 (https://doi.org/10.1001%2Fjama.29 g/10.1007%2Fs40256-013-0005-8). American Journal of
5.20.2346). PMID 16720816 (https://pubmed.ncbi.nlm.nih.gov/1672 Cardiovascular Drugs. 13 (1): 1–4. doi:10.1007/s40256-013-0005-8
0816). (https://doi.org/10.1007%2Fs40256-013-0005-8). PMID 23355360
(https://pubmed.ncbi.nlm.nih.gov/23355360). S2CID 13071864 (http
33. "Measles" (https://www.who.int/news-room/fact-sheets/detail/measl s://api.semanticscholar.org/CorpusID:13071864).
es). www.who.int. Retrieved 2023-06-16.
49. Bagnoli, F.; Bertholet, S.; Grandi, G. (2012). "Inferring Reasons for
34. "MERS vaccine shows promise in clinical trial, say researchers" (htt the Failure of Staphylococcus aureus Vaccines in Clinical Trials" (ht
ps://web.archive.org/web/20200503002825/https://www.europeanp tps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3417391). Frontiers in
harmaceuticalreview.com/news/117962/mers-vaccine-shows-promi Cellular and Infection Microbiology. 2: 16.
se-in-clinical-trial-say-researchers/). Archived from the original (http doi:10.3389/fcimb.2012.00016 (https://doi.org/10.3389%2Ffcimb.20
s://www.europeanpharmaceuticalreview.com/news/117962/mers-va 12.00016). PMC 3417391 (https://www.ncbi.nlm.nih.gov/pmc/article
ccine-shows-promise-in-clinical-trial-say-researchers/) on 2020-05- s/PMC3417391). PMID 22919608 (https://pubmed.ncbi.nlm.nih.gov/
03. 22919608).
35. "Developing a vaccine against Nipah virus" (https://www.sciencedai 50. https://www.who.int/news-room/fact-sheets/detail/trachoma (https://
ly.com/releases/2019/04/190415081956.htm#:~:text=Summary%3 www.who.int/news-room/fact-sheets/detail/trachoma). {{cite
A,viruses%20in%20the%20same%20family.&text=Nipah%20viru web}}: Missing or empty |title= (help)
s%20is%20a%20type,transmitted%20from%20animals%20to%20h
umans.). 51. Conlan, J. W. (2011). "Tularemia vaccines: Recent developments
and remaining hurdles". Future Microbiology. 6 (4): 391–405.
36. Sifferlin, A. (March 22, 2013). "Norovirus leading cause of intestinal
doi:10.2217/fmb.11.22 (https://doi.org/10.2217%2Ffmb.11.22).
disorders in kids" (http://www.cnn.com/2013/03/22/health/norovirus-
PMID 21526941 (https://pubmed.ncbi.nlm.nih.gov/21526941).
intestinal-disorders-time). CNN. Retrieved April 24, 2013.
52. Walsh TJ, Dixon DM (1996). Baron S, et al. (eds.). Spectrum of
37. "Onchocerciasis (river blindness)" (https://www.who.int/news-room/f
Mycoses. In: Baron's Medical Microbiology (4th ed.). Univ of Texas
act-sheets/detail/onchocerciasis). www.who.int. Retrieved
Medical Branch. ISBN 0-9631172-1-1. (via NCBI Bookshelf) (https://
2023-06-16.
www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=mmed.section.4006).
38. Sanjit Bagchi (April 26, 2006). "Study raises hopes of vaccine for
53. Hall, R. A.; Khromykh, A. A. (2004). "West Nile virus vaccines".
river blindness" (http://www.scidev.net/en/news/study-raises-hopes-
Expert Opinion on Biological Therapy. 4 (8): 1295–1305.
of-vaccine-for-river-blindness.html). SciDev Net. Retrieved April 24, doi:10.1517/14712598.4.8.1295 (https://doi.org/10.1517%2F14712
2013.
598.4.8.1295). PMID 15268663 (https://pubmed.ncbi.nlm.nih.gov/15
39. "Rabies" (https://www.who.int/news-room/fact-sheets/detail/rabies). 268663). S2CID 34176756 (https://api.semanticscholar.org/CorpusI
www.who.int. Retrieved 2023-06-16. D:34176756).
54. Sifferlin, Alexandra (21 January 2016). "U.S. Launches 'Full-court
Press' for a Zika Vaccine" (http://time.com/4188973/zika-virus-vacci
ne-nih/). Time. Retrieved 23 January 2016.
Chin J. B., ed. Control of Communicable Diseases Manual. 17th ed. APHA [American Public Health Association] Press; 2000. ISBN 978-0-
87553-189-2
Red Book: 2009 Report of the Committee on Infectious Diseases. 2009. American Academy of Pediatrics. 28th ed. ISBN 978-1-58110-306-9
Centers for Disease Control and Prevention. CDC Works 24/7 (https://www.cdc.gov). Retrieved on August 4, 2009.